DR. DINESH KHANNA (Orcid ID : 0000-0003-1412-4453)

DR. RAJAN SAGGAR (Orcid ID : 0000-0002-5536-5934)

Article type : Full Length

Long-Term Outcomes in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries

Dinesh Khanna, MD, MSc1; Carol Zhao, MS2; Rajan Saggar, MD3; Stephen C. Mathai, MD, MHS4; Lorinda S. Chung, MD, MS5; J. Gerry Coghlan, MD6; Mehul Shah, MD, PhD2; John Hartney, PhD2; Vallerie McLaughlin, MD, FACC, FCCP1

1University of Michigan, Ann Arbor, MI, USA; 2Actelion Pharmaceuticals US, Inc., South San Francisco, CA, USA; 3David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; 4Johns Hopkins University School of Medicine, Baltimore, MD, USA; 5Stanford University, Palo Alto, CA, USA; 6Royal Free Hospital London, London, UK

Running head: CTD-PAH meta-analysis

Declaration of interests

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ART.41669

This article is protected by copyright. All rights reserved
Dinesh Khanna reports consulting fees from Actelion (>$10,000), Acceleron (<$10,000), Bayer (>$10,000), BMS (<$10,000), Boehringer Ingelheim (>$10,000), Corbus (>$10,000), CSL Behring (>$10,000), Horizon (>$10,000), Gilead (<$10,000), Genentech/Roche (<$10,000), GSK (<$10,000), Mitsubishi Tanabe (<$10,000), Sanofi Aventis/Genzyme (<$10,000), and holds stock in Eicos Sciences, Inc.

Carol Zhao is an employee of Actelion Pharmaceuticals US, Inc. and stockholder in Johnson & Johnson, the parent company of Janssen Pharmaceuticals.

Rajan Saggar reports consulting fees, research funding, and speaker bureau fees from Actelion (>$10,000), Gilead Science (>$10,000), and United Therapeutics (>$10,000).

Stephen C. Mathai reports consulting fees from Actelion (>$10,000), Arena (<$10,000), Liquidia (<$10,000), and United Therapeutics (>$10,000).

Lorinda S. Chung reports consulting fees from Boehringer Ingelheim (>$10,000), Bristol Myers Squibb (<$10,000), Eicos (<$10,000), and Mitsubishi Tanabe (<$10,000); and research funding from Boehringer Ingelheim and United Therapeutics. She has served on a data safety monitoring board for Reata.

J. Gerry Coghlan reports consulting fees and speaker bureau fees from Bayer (<$10,000), GSK (<$10,000), and Johnson & Johnson (>$10,000); and research funding from Johnson & Johnson.

Mehul Shah is an employee of Actelion Pharmaceuticals US, Inc. and stockholder in Johnson & Johnson, the parent company of Janssen Pharmaceuticals.

John Hartney is an employee of Actelion Pharmaceuticals US, Inc. and stockholder in Johnson & Johnson, the parent company of Janssen Pharmaceuticals.

Vallerie McLaughlin reports consulting fees from Actelion Pharmaceuticals (>$10,000), Acceleron (>$10,000), Altavant (<$10,000), Arena Pharmaceuticals (>$10,000), Bayer (>$10,000), Caremark (<$10,000), CiVi Biopharma (<$10,000), Gossamer Bio (<$10,000) and United Therapeutics (>$10,000); and research funding from Acceleron,
Objective

Data on the magnitude of benefit of modern pulmonary arterial hypertension (PAH) therapies in connective tissue disease-associated PAH (CTD-PAH) are limited. We performed meta-analyses of randomized, controlled trials (RCTs) and registries to quantify this benefit (PROSPERO# CRD42020167119).

Methods

PubMed and EMBASE were searched for articles reporting data from RCTs or registries published 1/1/2000–11/25/2019. Eligibility criteria included multicenter studies with ≥30 CTD-PAH patients. RCTs had to evaluate approved PAH therapy and report long-term clinical morbidity/mortality or 6-minute walk distance. Registries had to report survival. Random effects models were used to pool data.

Results

This article is protected by copyright. All rights reserved
Eleven RCTs (N=4329 n=1267 CTD-PAH) and 19 registries (N=9739; n=4008 CTD-PAH) were included. Investigational therapy produced a 36% reduction in risk of clinical morbidity/mortality events versus control (HR=0.64; 95%CI: 0.54–0.75; \( P<0.001 \)) in all patients and a 36% reduction (HR=0.64; 95% CI: 0.51–0.81; \( P<0.001 \)) in CTD-PAH patients. Survival was lower in CTD-PAH versus all patients (62%, 95% CI: 57%–67% versus 72%, 95% CI: 69%–75% at 3 years). Survival in CTD-PAH patients treated primarily after 2010 was higher than in those treated before (73%, 95% CI: 62%–81% versus 65%, 95% CI: 59%–71% at 3 years).

Conclusions

Modern therapy provides a similar reduction in morbidity/mortality risk in CTD-PAH and the overall PAH population. Risk of death is higher in CTD-PAH than in PAH overall, but survival has improved in the last 10 years, which may be related to increased screening and/or new treatment approaches. Early detection of PAH in patients with CTD and upfront intensive treatment are warranted.

INTRODUCTION

Pulmonary arterial hypertension (PAH) leads to right ventricular dysfunction and failure with a median survival of approximately 3 years from the time of diagnosis (1, 2). Connective tissue disease-associated PAH (CTD-PAH) is historically associated with shortened survival compared to idiopathic PAH (IPAH) (3–6). Early detection of PAH with established methods among patients with CTD, such as systemic sclerosis (SSc) (7), and subsequent early treatment may improve survival outcomes (8). Rheumatologists are in a unique and critical position to identify these patients.

Availability of new and combination therapy approaches targeting multiple pathophysiological pathways have improved outcomes in PAH (9–16). However, trials of PAH therapies generally enroll patients with all PAH etiologies, and trials devoted
solely to CTD-PAH are rare; therefore, the magnitude of treatment effect in CTD-PAH is poorly defined as these patients represent a subgroup in most trials, albeit a large one. Further, data on whether new treatment approaches have resulted in improved survival in CTD-PAH are lacking.

We conducted 2 meta-analyses: we analyzed randomized, controlled trials (RCTs) to evaluate the magnitude of benefit of US Food and Drug Administration (FDA)-approved PAH therapies in patients with CTD-PAH, and we analyzed real-world observational disease registries to evaluate survival outcomes for patients with CTD-PAH as compared to the overall PAH population, and between patients treated mostly before or mostly after 2010. Compared to prior meta-analyses that have evaluated outcomes in RCTs among patients with CTD-PAH (17,18), our RCT meta-analysis provides a more contemporary dataset that includes modern agents and treatment paradigms, as well as a larger sample size. Our second meta-analysis extends these findings by evaluating long-term survival outcomes, an endpoint that is not typically included in RCTs because of their shorter duration. We also investigated survival over time to determine whether the availability of newer therapies and treatment approaches has translated into improved survival in real-world settings.

PATIENTS AND METHODS

These meta-analyses were conducted according to Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines (19) with a modification suited to the rare disease state of PAH. Specifically, we conducted a comprehensive literature search instead of a systematic review to identify peer-reviewed reports of RCTs evaluating new therapies and disease registries. We did not expand the search to databases beyond PubMed and Embase, nor did we examine reference lists and non-database sources for additional information because of the very low likelihood of this method yielding additional articles in this rare disease.

The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; #CRD42020167119) (20).
Search strategy and selection criteria

PubMed and Embase (Elsevier) were searched for English-only articles reporting data from RCTs or registries and published between January 1, 2000, and November 25, 2019. Search terms for RCTs were “pulmonary arterial hypertension” in the title AND (randomized OR randomised), restricted to human subjects, in PubMed and (‘pulmonary hypertension’/exp OR ‘pulmonary hypertension’), restricted to phase 3 or 4 randomized, controlled studies, in Embase. Search terms for registries were “pulmonary arterial hypertension” in the title AND (registry OR observation OR consecutive OR multicenter OR multicentre), restricted to human subjects, in PubMed and ‘pulmonary hypertension’ in the title AND (‘observational study’/exp OR ‘observational study’) in Embase.

Studies were included if the RCT or registry was conducted at multiple centers; enrolled adults with World Health Organization (WHO) Group 1 pulmonary hypertension (i.e., PAH) (21); included ≥30 patients with CTD-PAH; provided CTD-PAH subgroup identification with publicly available CTD-PAH–specific outcomes data; enrolled patients in the year 2000 or later; and reported long-term clinical morbidity and/or mortality (median enrollment time of ≥6 months). Only peer-reviewed data were included.

Additional inclusion criteria for RCTs were: phase 3 or 4; the evaluated PAH therapy must be currently FDA-approved; ≥3 months’ exposure to study drug for PAH treatment; and time-to-morbidity/mortality, time-to-clinical worsening, or 6-minute walk distance (6MWD), measured 3 to 6 months from baseline, had to have been a defined primary or secondary endpoint.

To minimize the risk of bias in study selection, we utilized strict pre-specified inclusion/exclusion criteria (as noted above). This involved a detailed review of each study design, patient inclusion and exclusion criteria, and definition of study endpoints. Studies not meeting the pre-specified criteria were excluded. In addition, at least 2 reviewers independently verified the studies that were to be included in the analyses, with any disagreements arbitrated by the lead and senior authors.
Publications providing the same data were removed. For multiple publications from 1 study, the most recent publication containing data on the CTD population was utilized. Data from all primary manuscripts of RCTs were included in the analysis for all PAH patients and CTD-PAH patients unless more detailed information for CTD-PAH patients were included in later post hoc analyses. When we extracted data from the post hoc analyses of the CTD-PAH subgroup, we ensured the number of patients in the CTD-PAH subgroup and the statistical analysis method were consistent with data from the primary manuscript. If multiple registries were conducted in 1 country, only studies that did not substantially overlap in enrollment period were included to avoid capturing data from the same patient in multiple registries.

Data were extracted from RCT and registry publications separately by 2 team members (with medical, science, or statistical expertise) under the leadership of statisticians at Actelion Pharmaceuticals. Extracted data were verified by a third team member independently. In the event of a discrepancy, a statistician verified the data prior to final statistical analysis and JH arbitrated any disagreements.

Data were extracted for patients with all PAH etiologies and for CTD-PAH separately. Baseline data extracted for both RCTs and registries were 6MWD, age, sex, WHO functional class (FC), and PAH etiology. Post-baseline data extracted were change from baseline in 6MWD between 3 and 6 months, number of clinical morbidity/mortality events, and hazard ratio (HR) from RCTs; and from registries, survival rates at 1, 2, and 3 years as reported or from Kaplan-Meier curves using a graph digitizer.

**Data analysis**

The meta-analysis of RCTs evaluated the effect of PAH therapies on time to clinical morbidity and/or mortality in all patients and patients with CTD-PAH, as well as the effect on 6MWD measured between 3 and 6 months after initiation of study treatment. The components of the clinical morbidity/mortality endpoints varied among the studies (Supplementary Table S1). The meta-analysis of registries evaluated survival outcomes in all patients and in patients with CTD-PAH. Analysis populations are defined in Supplementary Table S2.
To assess heterogeneity among studies, we calculated \( I^2 \) associated with the fixed effects meta-analysis models. These values indicated high heterogeneity for most analyses using fixed effects models but acceptable \( I^2 \) values using random effects meta-analysis models (Supplementary Table S3). Thus, we controlled for heterogeneity by consistently using random effects meta-analysis models to pool results using inverse variance weighting followed by un-weighting by applying a random effects variance component. The overall treatment effect estimate was calculated using the DerSimonian and Laird random effects method (22).

Time-to-event endpoints were estimated using the Kaplan-Meier method. Survival rates at 1-, 2-, and 3 years in registries were extracted from Kaplan-Meier curves and were stratified by study period mostly before or after 2010 to assess the impact of newer treatment approaches. Outcomes were analyzed for the overall PAH population and stratified by disease etiology (all CTD-PAH patients and CTD-PAH subtypes [SSc or systemic lupus erythematosus (SLE), or IPAH]). Registries with \( \geq 50\% \) of the study period in 2010 or later were classified as the after-2010 group.

Sensitivity analyses included analysis of treatment effect in RCTs in IPAH compared with CTD-PAH. In registries, analysis of survival rate in selected studies containing both CTD-PAH and other etiologies was performed to confirm the historical difference between etiologies.

A forest plot showing the effect size and associated variability in each study, as well as the combined effect, was created to examine the consistency of results. If any outliers were apparent, the data extraction was verified from the original source and the units were confirmed to ensure that no unit conversion was necessary. If, after this, an outlier was detected, a sensitivity analysis removing the outlier could be conducted to assess the impact on the overall analysis. However, no such outliers were found in our analysis.

Statistical analyses were performed with Comprehensive Meta-Analysis Version 3 Software (Biostat, Englewood, NJ).
Role of funding source

DK, VM, CZ, JH, SM, GC, and MS contributed to the study design. Employees of the study funder collected (CZ, JH, MS) and analyzed (CZ) the data. All authors had full access to the data, contributed to data interpretation, contributed to manuscript writing, and had final responsibility for the decision to submit for publication.

RESULTS

For RCTs, a total of 801 articles were identified through our comprehensive search strategy (Supplementary Figure S1) and 11 studies were ultimately included in the meta-analysis (Supplementary Table S4). For the primary endpoint, 5 RCTs reported time-to-clinical morbidity/mortality event (as defined in Supplementary Table S1) (12–16,23,24) and 6 RCTs reported change in 6MWD (10,11,25–30). The 11 RCTs enrolled 4329 patients with PAH, including 1267 patients with CTD-PAH (29.3%). Each RCT evaluated the addition of a PAH-specific therapy to a patient’s current care, which could have included no PAH-specific treatment, monotherapy, or dual combination therapy.

For registries, a total of 1389 articles were identified through our search (Supplementary Figure S2) and 19 registries were ultimately included in the meta-analysis: 9 enrolled patients with PAH of all etiologies (4,5,31–37) and 10 enrolled only patients with CTD-PAH (Supplementary Table S5) (38–47). The 19 registries enrolled 9739 patients with PAH, including 4008 patients with CTD-PAH (41.2%).

At baseline, patients with CTD-PAH had an older mean age and lower mean 6MWD compared to the overall PAH population in both the RCTs and registries. In RCTs, overall, patients had a mean age of 50 years, 78%–79% were female, and 41%–43%
had FC I–II disease (Table 1). Patients with CTD-PAH had a mean age of 55–56 years versus 50 years among patients of all PAH etiologies (Supplementary Table S6) and had a mean 6MWD of 337–339 m versus 355–357 m among patients of all PAH etiologies (Supplementary Table S7).

In all 16 registries that reported baseline characteristics separately for the CTD-PAH population, patients with CTD-PAH had a mean age of 55 years, 87% were female, 30% had FC I–II disease, and the mean 6MWD was 327 m (Supplementary Table S8). From the 9 registries that enrolled patients with all PAH etiologies, all patients had a mean age of 51 years, 74% were female, 28% had FC I–II disease, and the mean 6MWD was 348 m; and patients with CTD-PAH had a mean age of 56 years, 84% were female, 24% had FC I–II disease, and the mean 6MWD was 328 m (Table 2). Baseline data from registries for the CTD-PAH subgroups treated before and after 2010 are shown in Supplementary Table S9. Baseline data from registries for the CTD-PAH subgroups of SSc and SLE are shown in Supplementary Table S10.

**Outcomes from RCTs**

The 5 RCTs that reported time-to-clinical morbidity/mortality event as the primary endpoint enrolled 3172 patients (n=941 with CTD-PAH [30%]) (12–16,23,24). Additional PAH therapy resulted in a 36% reduction in risk of morbidity/mortality events compared to control (HR=0.64; 95% CI: 0.54–0.75; \( P < 0.001 \)) in the overall PAH population and a 36% reduction (HR=0.64; 95% CI: 0.51–0.81; \( P < 0.001 \)) in patients with CTD-PAH (Figure 1).

Additional PAH therapy led to a placebo- or monotherapy-corrected increase in 6MWD of 28.6 m (95% CI: 19.2–38.0; \( P < 0.001 \)) in the overall PAH population (Figure 2A). Eight RCTs (N=2874; n=882 with CTD-PAH [31%]) reported this endpoint by CTD-PAH etiology (9–12,15,23–30). Additional PAH therapy led to an increase in 6MWD of 34.6 m (95% CI: 22.1–47.1; \( P < 0.001 \)) in the overall PAH population and 20.4 m (95% CI: 10.9–29.9; \( P < 0.001 \)) in patients with CTD-PAH (Figure 2B and Figure 2C).
Sensitivity analyses were performed to compare outcomes between patients with CTD-PAH and IPAH among the subset of trials that reported outcomes separately in the IPAH subpopulation. Results from patients with IPAH trended similar to the overall PAH population (HR=0.63; 95% CI: 0.54–0.73; \( P<0.001 \)).

**Outcomes from registries**

Among 9 registries that included patients with PAH irrespective of etiology (4,5,31,32–37), survival rates in patients with CTD-PAH (n=2113) were lower than in the overall PAH population (N=7829) (Figure 3A).

Among all CTD-PAH patients with available data, including those from both all-PAH and CTD-PAH–specific registries (19 registries; n=3978), survival rates in patients with CTD-PAH treated in registries with \( \geq 50\% \) of the study period during or after 2010 (n=1819) were higher than in those treated in registries with \( \geq 50\% \) of the study period occurring before 2010 (n=2159) (Figure 3B).

Among all patients with CTD-PAH, survival rates were lower for those with SSc (n=1485) (36,38,41,43,44,46,47) compared to those with SLE (n=456) (39,40,42,45) (Figure 3C).

**DISCUSSION**

Our meta-analysis of RCTs demonstrated that patients with CTD-PAH derive a clinically significant benefit from currently available PAH therapies which, in many patients, comprised the addition of a drug targeting a second or third pathway involved in the pathophysiology of PAH. Our meta-analysis of registries showed that patients with CTD-PAH have a higher risk of death than the overall PAH population; however, survival has improved among the CTD-PAH population treated mostly in the last 10 years compared to earlier patient populations.

Two other relatively recent meta-analyses have also evaluated the benefit of PAH-specific therapy in patients with CTD-PAH (17,18). Rhee and colleagues (17) evaluated individual patient data from 11 RCTs published between 2002 and 2013 (n=2762;...
n=827 with CTD-PAH [30%]). Most of the trials (59% of patients) evaluated endothelin receptor antagonists (ERAs). Similar to our 6MWD results, patients with CTD-PAH experienced less benefit than patients with IPAH. The mean placebo-corrected treatment effect in change in 6MWD from baseline to 3 months was 23.1 m (CTD-PAH) versus 40.4 m (IPAH; adjusted treatment effect difference, -17.3 m; 90% CI, -31.3 to -3.3; \( P \)-value for interaction=0.043). We reported a similar placebo-/monotherapy-corrected change in 6MWD of 20.4 m in patients with CTD-PAH. Our reference population included patients with all PAH etiologies, which may explain the lower benefit of 34.6 m observed in our study compared to those with IPAH reported by Rhee and colleagues (17). However, earlier meta-analyses of 6MWD from RCTs are also conflicting with 1 showing similar benefit in patients with CTD-PAH and PAH of all etiologies (48) and another showing no benefit in patients with CTD-PAH (49). Time-to-clinical worsening was not significantly prolonged among patients with CTD-PAH in the meta-analysis by Rhee and colleagues (17) with an odds ratio of 0.72 (95% CI, 0.45–1.16); whereas we demonstrated a benefit (HR, 0.64; 95% CI, 0.51–0.80). The difference between meta-analyses may result from several factors. We believe that our analysis provides a more precise estimate of treatment effect because we applied more stringent statistical methods to pool the studies. Specifically, we measured the time to a clinical morbidity/mortality event by using the hazard ratio, which averages the treatment effect over the entire study period. Rhee and colleagues measured clinical worsening events using an odds ratio, which is affected by differences in study duration. Further, our study required a median study duration of ≥6 months to capture long-term clinical morbidity and mortality (current standards to assess overall benefit), whereas approximately half of the trials included by Rhee and colleagues (17) were of 12- to 18-weeks duration (i.e., a previous standard to assess PAH therapy efficacy). Finally, we used a more contemporary dataset, which included trials of the most recently available PAH therapies comprising oral ERAs, phosphodiesterase type 5 inhibitors, oral prostacyclin pathway agents, and riociguat, as well as more use of combination therapy. This dataset, thus, more accurately reflects current treatment approaches. This approach also resulted in a larger patient population (1267 CTD-PAH patients from
RCTs compared with 827 in the analysis by Rhee and colleagues), which increases the precision of the statistical estimates.

Pan and colleagues (18) analyzed data extracted from 6 RCTs published between 2011 and 2017 (n=3262; n=963 with CTD-PAH [30%]). These trials evaluated ERAs, tadalafil, selexipag, and riociguat. This meta-analysis aimed to compare combination therapy versus monotherapy; however, background therapy varied among studies and patients within the studies. Among 4 RCTs in the CTD-PAH subset included in the analysis, additional PAH therapy led to a 27% relative risk reduction of clinical worsening (pooled relative risk, 0.73 [95% CI, 0.60–0.89], \( P=0.002 \)). These data are consistent with our finding of a 36% reduction in risk of a clinical morbidity/mortality event in the CTD-PAH population. There were differences in methodology between the 2 analyses. In our study, for clinical relevance, only treatment arms receiving FDA-approved doses were analyzed. Additionally, our meta-analysis includes the more recently published FREEDOM-EV trial (16), which was published after the Pan and colleague’s (18) meta-analysis was completed. Pan and colleagues also found no statistically significant benefit in change in 6MWD among patients with CTD-PAH with additional therapy (21.38 m; 95% CI, -20.38 to 63.14; \( P=0.32 \)). This endpoint was derived from 3 RCTs. Our meta-analysis, which included 8 trials for this endpoint, demonstrated a similar numerical benefit for patients with CTD-PAH that was statistically significant (20.4 m; 95% CI, 10.9 to 29.9; \( P<0.001 \)), perhaps reflecting greater statistical power due to increased sample size. Overall, compared to the Pan and colleague’s (18) meta-analysis, our study provides an expanded evaluation, including the FREEDOM-EV trial, with an additional meta-analysis of survival in registries because long-term survival outcomes and longitudinal analysis of survival outcomes over decades are inaccessible from RCTs.

Patients with CTD-PAH have a substantial risk of death; however, patients with CTD-PAH who were treated within the last 10 years have numerically higher survival rates than those treated earlier. This difference may be related to increased screening for PAH, especially in SSc. Increased screening leads to earlier diagnosis, which provides the opportunity for earlier management (8) but also introduces lead-time bias (50). If...
lead-time bias is present, patients in later registries would be expected to be younger with less severe disease. Our analysis found that in the later registries, patients were older (mean age 57 years vs 54 years), but had less severe disease (as defined by proportion of patients with FC I-II disease, 40% versus 23%, respectively) and greater 6MWD (336 m vs 321 m; Supplemental Table S9). Whether lead-time bias is playing a substantial role in our results cannot be definitively determined from the current analysis.

The difference in survival over time also may reflect the availability of new treatment approaches. The survival improvement is likely underestimated since just 6 registries (32%) enrolled patients in 2015 or later, when all currently available treatments were in use and early combination therapy became more prevalent (5,34,39,41,46,47). More recent data are available from the United Kingdom Pulmonary Hypertension Audit (51). The most recent peer-reviewed published data from this database are included in our meta-analysis (38); however, the latest report available (data from 2009-2019) is not included due to lack of peer review. Published data from 2001–2007 reported 1-, 2-, and 3-year survival rates among patients with SSc-associated PAH of 78%, 58%, and 47%, respectively. Corresponding survival rates from 2009–2019 were 81%, 61%, and 55%, respectively. These data corroborate the improved survival rates observed over time in our meta-analysis. Consistent with clinical observations and published data (6,38,52), our meta-analysis demonstrated that patients with SSc have worse survival rates than those with SLE. It should be noted, however, that patients with SSc in our analysis were older than those with SLE and appeared to have more severe disease as indicated by fewer patients with FC I/II disease and shorter 6MWD (Supplementary Table S10) which likely also contributed to their poorer survival. We were not able to use meta-analysis to compare the treatment effect in RCTs in patients with SSc versus those with SLE since only two RCTs provided sufficient data on patients with SSc (23, 24) and one on patients with SLE (24).

Because all-cause mortality was evaluated, we may be overestimating death due to PAH among patients with CTD-PAH. These patients are older and experience greater comorbidity burden than the overall PAH population. As such, these patients are
possibly frailer and may die from causes other than their PAH. Although registries are subject to bias, these sources of long-term data and larger sample size were deemed important to include in order to provide prolonged survival data unavailable from RCTs. Current guidelines now recommend combination therapy and more intensive therapy regardless of PAH etiology (53), and our meta-analysis of registries provides evidence suggesting that the modern approach to treatment is improving survival in CTD-PAH. Nonetheless, survival remains lower for these patients, highlighting the need for continued research into the best treatment approaches and screening programs to promote early diagnosis and prompt management. Additional avenues for research to improve outcomes in this population include standardized reporting of comorbidities, which can substantially impact outcomes in CTD-PAH, as well as in PAH of other etiologies (54). Identification of comorbidities is further complicated by lack of a consensus definition of significant interstitial lung disease in SSc. An additional area of focus should be standardized reporting of baseline risk profiles, since data suggest that patients with CTD-PAH are at greater risk of death despite a less severe hemodynamic phenotype (5,55). Identification of clinically relevant changes in outcome measures, which may differ among PAH subtypes, would also be helpful. Finally, the era of personalized medicines may enable smaller study sizes and ultimately facilitate the discovery of treatment approaches that show greater benefit within CTD-PAH populations.

A strength of our meta-analyses is the inclusion of only trials evaluating therapies that are approved for PAH treatment. By limiting RCTs to approved therapies, the results better reflect the benefit that can be observed in real-world settings. In addition, our meta-analysis of RCTs assessed the impact of current PAH treatments on morbidity and mortality, as endorsed by the 6th World Symposium on Pulmonary Hypertension (53). A limitation of our meta-analysis of RCTs was that definitions of a clinical morbidity/mortality event varied to a limited extent across studies (Supplementary Table S1). A limitation of our meta-analysis of registries was the limited availability of studies that enrolled patients from 2015 onward to provide a survival estimate consistent with that observed in modern clinical practice. In all analyses, the overall PAH population to which we compared the CTD-PAH population included patients with CTD-PAH because...
not all studies provided IPAH-specific data. However, sensitivity analyses of RCTs that provided IPAH-specific data, demonstrated similar trends with IPAH versus CTD-PAH as with all PAH etiologies versus CTD-PAH. An additional limitation is that the extent to which the treatment effect is influenced by different background therapies, potential variability in exposure to therapies, concomitant medications (such as immunosuppressants), as well as different proportions of newly and previously diagnosed patients, in the study populations is unknown. Finally, the diagnosis of PAH was accepted per each study or registry criteria; it is possible that underlying conditions, such as pulmonary veno-occlusive disease and concomitant ILD, were present and to differing degrees among the various studies. A limitation of our search methodology was that we did not search additional databases beyond PubMed and Embase. As noted, however, we do not expect any differences in outcomes as a result of this given the parameters of our meta-analyses, the rarity of this disease state, and the relatively small number of studies reporting data separately for the subset of patients with CTD-PAH.

In conclusion, these complementary meta-analyses of RCTs and observational disease registries demonstrated that patients with CTD-PAH had a similar reduction in the risk of clinical morbidity and mortality events as the overall PAH population with modern PAH treatments. The improvement in 6MWD in patients with CTD-PAH appeared smaller than in those with other types of PAH, perhaps reflecting comorbidities (such as musculoskeletal involvement), independent of their cardiopulmonary capacity. Patients with CTD-PAH have a higher risk of death than the overall PAH population; however, survival has improved among this subgroup treated in the last 10 years compared to earlier cohorts. Patients with SSc have worse survival rates than those with SLE. Given the high risk of mortality in these patients, early detection and upfront aggressive treatment are warranted (56).

Acknowledgments

This article is protected by copyright. All rights reserved
Funding for this analysis was provided by Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. The authors would like to thank Saling Huang, PhD, for consulting on the statistical analysis, and Kristine Jermakian for her contributions to the comprehensive review and data extraction. Medical writing support was provided by Holly Strausbaugh, PhD, and Laura Evans, PharmD, on behalf of Twist Medical, LLC, and funded by Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

References

1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67–119.

2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–9.

3. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34–41.

4. Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549–55.

5. Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017;50:1700740.
6. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010;138:1383–94.

7. Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, et al. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Semin Arthritis Rheum 2019;48:1059–67.

8. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011;63:3522–30.

9. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148–57.

10. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894–903.

11. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330–40.

12. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834–44.

13. McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46:405–13.
14. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809–18.

15. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522–33.

16. White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension: A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med 2020;201:707–17.

17. Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM. Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1111–7.

18. Pan J, Lei L, Zhao C. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol 2018;36:1095–102.

19. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.

20. National Institute for Health Research. PROSPERO: International prospective register of systematic reviews. https://www.crd.york.ac.uk/prospero/. Accessed March 16, 2020.

21. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.

23. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017;76:1219–27.

24. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 2017;50:1602493.

25. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.

26. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336–40.

27. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417–22.

28. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010–9.

29. Badesch DB. Ambrisentan therapy for pulmonary arterial hypertension: a comparison by PAH etiology. Chest 2007;132(suppl):488b–9 (abstr).
30. Galiè N, Denton CP, Dardi F, Manes A, Mazzanti G, Li B, et al. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. Int J Cardiol 2017;235:67–72.

31. Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012;40:596–603.

32. McLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, et al. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest 2013;143:324–32.

33. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012;142:448–56.

34. Yaylalı YT, Başarıcı I, Kılıçkıran Avcı B, Meriç M, Sinan UY, Şenol H, et al. Risk assessment and survival of patients with pulmonary hypertension: multicenter experience in Turkey. Anatol J Cardiol 2019;21:322–30.

35. Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011;140:301–9.

36. Keogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S, et al. The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension. Intern Med J 2011;41:227–34.

37. Chung WJ, Park YB, Jeon CH, Jung JW, Ko KP, Choi SJ, et al. Baseline characteristics of the Korean registry of pulmonary arterial hypertension. J Korean Med Sci 2015;30:1429–38.

38. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151–7.
39. Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, et al. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J 2019;53:1800081.

40. Kang KY, Jeon CH, Choi SJ, Yoon BY, Choi CB, Lee CH, et al. Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry. Int J Rheum Dis 2017;20:1227–36.

41. Kolstad KD, Li S, Steen V, Chung L; PHAROS Investigators. Long-term outcomes in systemic sclerosis-associated pulmonary arterial hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest 2018;154:862–71.

42. Hao YJ, Jiang X, Zhou W, Wang Y, Gao L, Wang Y, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J 2014;44:963–72.

43. Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012;14:R213.

44. Launay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011;140:1016–24.

45. Hachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French pulmonary hypertension registry. Chest 2018;153:143–51.

46. Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, et al. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther 2017;19:122.
47. Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, et al. Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. Eur Respir J 2018;52:1800678.

48. Kuwana M, Watanabe H, Matsuoka N, Sugiyama N. Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. BMJ Open 2013;3:e003113.

49. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:808–14.

50. Weatherald J, Montani D, Jevnikar M, Jaïs X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019;28:190023.

51. NHS Digital. National audit of pulmonary hypertension: Great Britain, 2018-19. https://files.digital.nhs.uk/BA/4EF20E/NAPH%2010AR%20-%20Main%20Report.pdf. October 24, 2019. Accessed March 16, 2020.

52. Sobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J, et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 2016;68:484–93.

53. Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019;53:1801889.

54. Lewis RA, Thompson AAR, Billings CG, Charalampopoulos A, Elliot CA, Hamilton N, et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020;55:2000041

This article is protected by copyright. All rights reserved
55. Peacock AJ, Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, et al. Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype? Pulm Circ 2020;10:2045894020914851.

56. Nagaraja V, Cerinic MM, Furst DE, Kuwana M, Allanore Y, Denton CP, et al. Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis Rheumatol 2020;Mar 5. DOI: 10.1002/art.41246.

Figure legends

Figure 1. Time to clinical morbidity/mortality event for all patients (left panel) and patients with CTD-PAH (right panel) in randomized, controlled trials that evaluated time-to-clinical morbidity/mortality event as a primary endpoint (5 trials).

AMBITION=Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension; CI=confidence interval; CTD-PAH=connective tissue disease-associated pulmonary arterial hypertension; GRIPHON=Prostacyclin (PGI\(_2\)) Receptor Agonist in Pulmonary Arterial Hypertension; HR=hazard ratio; SERAPHIN=Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome.

Figure 2. Change in 6MWD for all patients in all randomized, controlled trials (A; 11 trials); for all patients in randomized, controlled trials that reported 6MWD in patients with CTD-PAH (B; 8 trials); and for patients with CTD-PAH (C; 8 trials). *Combined data from ARIES-1 and ARIES-2 presented. 6MWD=6-minute-walk distance;

AMBITION=Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension; ARIES=Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies; BREATHE-1=Bosentan Randomized Trial of Endothelin Antagonist Therapy; CI=confidence interval; CTD-PAH=connective tissue disease-associated pulmonary arterial hypertension; GRIPHON=Prostacyclin (PGI\(_2\)) Receptor Agonist in Pulmonary Arterial Hypertension; PATENT-1=Pulmonary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1; PHIRST=Pulmonary Arterial Hypertension and Response to Tadalafil; SERAPHIN=Study with an Endothelin Receptor Antagonist in Pulmonary Arterial
Hypertension to Improve Clinical Outcome; SUPER=Sildenafil Use in Pulmonary Arterial Hypertension.

**Figure 3.** Survival estimates (A) in patients by PAH etiology among registries in which all PAH etiologies were included (9 registries); (B) in patients with CTD-PAH from all registries (19 registries) by enrollment period; and (C) by CTD subtype from disease-specific registries or registries that included disease-specific outcomes (8 registries for SSc and 4 registries for SLE). Vertical bars represent 95% confidence intervals.

CTD=connective tissue disease; CTD-PAH=connective tissue disease-associated pulmonary arterial hypertension; PAH=pulmonary arterial hypertension; SLE=systemic lupus erythematosus; SSc=systemic sclerosis.
Table 1. Baseline characteristics of all patients in randomized, controlled trials

| Study (ref.)     | N  | Mean Age, y (SD) | Female, % | FC I–II, % | N  | Mean Age, y (SD) | Female, % | FC I–II, % |
|------------------|----|------------------|-----------|------------|----|------------------|-----------|------------|
| AMBITION (12)    | 253| 55 (14)          | 74        | 30         | 247| 54 (15)          | 81        | 32         |
| GRIPHON (15)     | 574| 48 (15)          | 80        | 48         | 582| 48 (16)          | 80        | 45         |
| SERAPHIN (14)    | 242| 45 (15)          | 80        | 50         | 250| 47 (17)          | 74        | 52         |
| PHIRST (10)      | 79 | 53 (15)          | 75        | 35         | 82 | 55 (15)          | 79        | 29         |
| ARIES-1 (28)     | 67 | 49 (16)          | 79        | 36         | 67 | 48 (16)          | 88        | 37         |
| ARIES-2 (28)     | 63 | 50 (16)          | 81        | 46         | 65 | 51 (14)          | 68        | 40         |
| PATENT (11)      | 254| 51 (17)          | 80        | 45         | 126| 51 (17)          | 78        | 51         |
| SUPER-1 (9)      | 71 | 48 (15)          | 79        | 39         | 70 | 49 (17)          | 81        | 47         |
| BREATHE-1 (25)   | 144| 49 (16)          | 79        | 0          | 69 | 47 (16)          | 78        | 0          |
| COMPASS-2 (13)   | 159| 53 (15)          | 79        | 45         | 175| 55 (16)          | 73        | 39         |
| FREEDOM EV (16)  | 346| 46 (16)          | 80        | 62         | 344| 45 (15)          | 78        | 70         |
| Overall*         | 2252| 50 (SE, 1.1)    | 79 (SE, 1.1)| 41 (SE, 1.2) | 2077| 50 (SE, 1.2)    | 78 (SE, 1.2)| 43         |

*estimated mean and standard error from the random effects model.

AMBITION=Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension; ARIES=Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies; BREATHE-1=Bosentan
Randomized Trial of Endothelin Antagonist Therapy; FC=functional class; GRIPHON=Prostacyclin (PGI$_2$) Receptor Agonist in Pulmonary Arterial Hypertension; PATENT=Pulmonary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1; PHIRST=Pulmonary Arterial Hypertension and Response to Tadalafil; ref.=reference; SD=standard deviation; SE=standard error; SERAPHIN=Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome; SUPER=Sildenafil Use in Pulmonary Arterial Hypertension.
Table 2. Baseline characteristics of patients in registries enrolling patients with PAH irrespective of etiology

| Registry (ref.) | All Patients (n=7844) | Patients with CTD-PAH (n=2113) |
|----------------|----------------------|-------------------------------|
|                | Mean Age, y (SD)     | Female, %                     | Mean Age, y (SD) | Female, % | FC I–II, % | Mean 6MWD, m (SD) | CTD, % | Mean Age, y (SD) | Female, % | FC I–II, % | Mean 6MWD, m (SD) |
| REHAP (31)     | 45 (17)              | 71                             | 363 (120)        | 18        |           | 54 (15)         | 90     | 21              |           | 309 (115) |
| PAH-QuERI (32) | 55 (16)              | 77                             | —                | 29        |           | —              | —      | —               | —         | —       |
| COMPERA (5)    | 64 (16)              | 64                             | 298 (126)        | 22        | 11        | 66 (13)         | 78     | 11              |           | 273 (130) |
| French PAH Network | 50 (15)   | 66                             | 329 (109)        | 15        | 25        | 56 (15)         | 80     | 26              |           | 315 (111) |
| Registry (4)   |                      |                                |                  |           |           |                 |        |                 |           |         |
| REVEAL (33)    | 50 (17)              | 77                             | —                | 28        |           | —              | —      | —               | —         | —       |
| THALES (34)    | 46 (17)              | 77                             | —                | 22        |           | —              | —      | —               | —         | —       |
| Chinese Registry-PAH (35) | 36 (15)   | 76                             | 390 (111)        | 37        | 46        | 42 (14)         | 85     | 45              |           | 384 (107) |
| BPR (36)       | 59 (17)              | 77                             | —                | 42        |           | 62 (11)         | 85     | 6               |           | —       |
| KORPAH (37)    | 50 (17)              | 78                             | 363 (116)        | 58        | 53        | 54 (17)         | 85     | 63              |           | 358 (114) |
| Overall†       | 51                   | 74                             | 348 (116)        | 29        | 28        | 56 (15)         | 84     | 24              |           | 328 (114) |
|                | (SE, 2.7)            | (SE, 16.4)                     | (SE, 3.3)        |           |           | (SE, 20.1)      |        |                 |           |         |

*estimated mean and standard error from the random effects model.

— Indicates not reported.
6MWD=6-minute-walk distance; BPR=Bosentan Patient Registry; COMPERA=Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; CTD=connective tissue disease; FC=functional class; KORPAH=Korean Registry of Pulmonary Arterial Hypertension; PAH=pulmonary arterial hypertension; PAH-QuERI=Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative; ref.=reference; REHAP=Spanish Registry of Pulmonary Arterial Hypertension; REVEAL=Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management; SD=standard deviation; SE=standard error.
| Study name (period)     | Active arm (n) | Control arm (n) | HR (95% CI) | Active arm (n) | Control arm (n) | HR (95% CI) |
|-------------------------|----------------|-----------------|-------------|----------------|-----------------|-------------|
| COMPASS-2 (May 2006–Dec 2013) | 159            | 175             | 0.83 (0.61–1.14) | 43             | 45              | 0.90 (0.51–1.59) |
| SERAPHIN (May 2008–March 2012) | 242            | 250             | 0.55 (0.41–0.74) | 73             | 81              | 0.58 (0.33–1.02) |
| GRIPHON (Dec 2009–April 2014) | 574            | 582             | 0.60 (0.49–0.73) | 167            | 167             | 0.59 (0.41–0.85) |
| FREEDOM-EV (June 2010–June 2018) | 346            | 344             | 0.74 (0.56–0.97) | 94             | 84              | 0.84 (0.50–1.41) |
| AMBITION (Oct 2010–July 2014) | 253            | 247             | 0.50 (0.35–0.72) | 103            | 84              | 0.43 (0.24–0.77) |
| Overall estimate        |                |                 | 0.64 (0.54–0.75) |                |                 | 0.64 (0.51–0.81) |

Note: Overall HRs were estimated using random effects models.

art_41669_f1.eps
